Andrew J. Armstrong

2007–2026 年に発表

191
論文数
29,246
被引用数
72
h 指数
168
i10 指数

被引用数

Andrew J. Armstrong の年別被引用数1994 年: 被引用 1 件1996 年: 被引用 1 件2004 年: 被引用 1 件2005 年: 被引用 1 件2008 年: 被引用 10 件2009 年: 被引用 16 件2010 年: 被引用 11 件2011 年: 被引用 29 件2012 年: 被引用 43 件2013 年: 被引用 172 件2014 年: 被引用 206 件2015 年: 被引用 231 件2016 年: 被引用 289 件2017 年: 被引用 273 件2018 年: 被引用 287 件2019 年: 被引用 1,007 件2020 年: 被引用 1,256 件2021 年: 被引用 1,363 件2022 年: 被引用 995 件2023 年: 被引用 875 件2024 年: 被引用 1,590 件2025 年: 被引用 809 件2026 年: 被引用 34 件1995 年は被引用が無いため表示していません1997〜2003 年は被引用が無いため表示していません2006〜2007 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,121 件、この内訳の 25.5%中国: 引用元論文 1,139 件、この内訳の 9.3%イギリス: 引用元論文 794 件、この内訳の 6.5%ドイツ: 引用元論文 704 件、この内訳の 5.8%カナダ: 引用元論文 668 件、この内訳の 5.5%イタリア: 引用元論文 625 件、この内訳の 5.1%フランス: 引用元論文 490 件、この内訳の 4%オーストラリア: 引用元論文 461 件、この内訳の 3.8%日本: 引用元論文 363 件、この内訳の 3%スペイン: 引用元論文 349 件、この内訳の 2.8%オランダ: 引用元論文 321 件、この内訳の 2.6%スイス: 引用元論文 284 件、この内訳の 2.3%
0%25.5%その他 23.8%

分野

  • Medicine77%
  • Biochemistry, Genetics and Molecular Biology16.4%
  • Immunology and Microbiology2.1%
  • Computer Science1.1%
  • Engineering1.1%
  • Mathematics0.3%
  • その他2%

トピック

  • Prostate Cancer Treatment and Research19%
  • Prostate Cancer Diagnosis and Treatment10.6%
  • Radiopharmaceutical Chemistry and Applications5%
  • Cancer, Lipids, and Metabolism3.2%
  • Cancer Genomics and Diagnostics3.2%
  • Cancer Cells and Metastasis3.1%
  • その他55.9%

共著者

全論文

検索で開く
  1. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 被引用: 4,574

  2. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 被引用: 1,603

  3. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 被引用: 3,031

  4. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 1,186

  5. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - NEJM Evidence 2022 被引用: 394

  6. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 288

  7. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 299

  8. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dorothy A. Shead, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2021 被引用: 530

  9. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki ほか 18 名 - European Journal of Cancer 2023 被引用: 157

  10. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan D. Tward, Dorothy A. Shead, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2019 被引用: 1,573

  11. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - NEJM Evidence 2023 被引用: 120

  12. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis

    著者: , , , , , , , , , , , , - Journal of Clinical Investigation 2023 被引用: 102

  13. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 364

  14. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

    著者: , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2023 被引用: 97

  15. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 463

  16. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 275

  17. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

    著者: , , , , , , , , , - European Urology 2020 被引用: 163

  18. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

    著者: , , , , , , , , , , , , , , , , , , , , - European Urology 2016 被引用: 419

  19. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hamid Emamekhoo, Alexander W. Wyatt, Joshua M. Lang, Shuang G. Zhao - Annals of Oncology 2023 被引用: 65

  20. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas

    著者: , , , , , , , , , - Pharmacology & Therapeutics 2018 被引用: 337

  21. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki ほか 18 名 - European Urology 2022 被引用: 118

  22. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew J. Armstrong, Qing Cheng, Jiaoti Huang - Science Translational Medicine 2019 被引用: 136

  23. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 424

  24. CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

    著者: , , , , , , , , , , , , , , , , - Investigational New Drugs 2024 被引用: 62